Rapid production of clinical-grade SARS-CoV-2 specific T cells.

ABSTRACT:

Objectives

To determine whether the frequencies of SARS-CoV-2-specific T cells are sufficiently high in the blood of convalescent donors and whether it is technically feasible to manufacture clinical-grade products overnight for T-cell therapy and assessment of COVID-19 immunity.

Methods

One unit of whole blood or leukapheresis was collected from each donor following standard blood bank practices. The leukocytes were stimulated using overlapping peptides of SARS-CoV-2, covering the immunodominant sequence domains of the S protein and the complete sequence of the N and M proteins. Thereafter, functionally reactive cells were enriched overnight using an automated device capturing IFNγ-secreting cells.

Results

From 1 × 10⁹ leukocytes, a median of 0.98 × 10

SUBMITTER: Leung W 

PROVIDER: S-EPMC7404427 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature